56 results
10-K
2018 FY
PHASQ
PhaseBio Pharmaceuticals Inc
26 Mar 19
Annual report
4:45pm
to healthcare professionals.
Coverage and Reimbursement
Market acceptance and sales of any drug products depend in part on coverage and the extent to which … adequate reimbursement for drug products will be available from third-party payors, including government health administration authorities, managed care
10-Q
2018 Q3
PHASQ
PhaseBio Pharmaceuticals Inc
29 Nov 18
Quarterly report
4:53pm
, 2018 as we incurred allowable costs qualifying for reimbursement under our government grants. We did not receive any grant revenues for the three … million for the nine months ended September 30, 2018 as we incurred allowable costs qualifying for reimbursement under our government grants. We did
8-K
EX-99.1
n49cu05
26 Mar 19
PhaseBio Reports Fourth Quarter and Full-Year 2018 Financial and Business Results
4:05pm
8-K
EX-10.1
nsipr
9 Apr 19
PhaseBio Announces Global License of PB1023 for the Treatment of Sarcopenia-Related Diseases to ImmunoForge
8:01am
424B4
fb2jl1efwmt2d8w688j
19 Oct 18
Prospectus supplement with pricing info
12:00am
DRS
h9l52rzyfjppeg
27 Jul 18
Draft registration statement
12:00am